인도의 신종 감염증 진단 시장 : 역학별, 용도별, 기술별, 감염 유형별, 질환 유형별, 최종 사용자별 - 분석과 예측(2025-2035년)

India Emerging Infectious Disease Diagnostics Market Industry Overview

India emerging infectious disease diagnostics market is experiencing rapid growth, driven by the increasing prevalence of infectious diseases, such as COVID-19, malaria, tuberculosis, and dengue, alongside rising concerns about antimicrobial resistance. Technological advancements in diagnostics, particularly in molecular diagnostics, point-of-care testing, and artificial intelligence, are enabling faster and more accurate detection of pathogens, which is crucial for effective disease management. The government's initiatives, such as the National Health Mission and investments in healthcare infrastructure, further bolster the growth of the market. Additionally, the private sector's involvement through diagnostic chains and partnerships with international companies is contributing to the expansion of diagnostic capabilities across India, particularly in underserved regions. The heightened awareness about health, accelerated by the COVID-19 pandemic, has also increased the demand for timely diagnostics. As a result, the market is evolving rapidly, with innovations and improved accessibility driving further advancements in the detection and treatment of emerging infectious diseases.

Several key factors are driving the growth of India's emerging infectious disease diagnostics market. Ongoing advancements in diagnostic technologies, particularly in molecular diagnostics such as PCR and RT-PCR, are enabling faster and more accurate detection of pathogens. The increasing prevalence of infectious diseases, including COVID-19, malaria, tuberculosis, and dengue, has heightened the demand for efficient diagnostic solutions. Furthermore, government initiatives such as the National Health Mission and investments in healthcare infrastructure are enhancing the availability and accessibility of diagnostic tools, particularly in rural areas. The growing awareness of public health and the emphasis on early disease detection, accelerated by the COVID-19 pandemic, have further contributed to market growth. Additionally, the rise of private diagnostic chains and partnerships with international diagnostic companies are increasing the reach of advanced diagnostic technologies across India. These factors collectively position the market for continued expansion, with innovations in diagnostic tools and greater healthcare accessibility playing a pivotal role in shaping its future.

Despite the significant opportunities, several challenges persist in India emerging infectious disease diagnostics market. One of the primary challenges is the uneven healthcare infrastructure, particularly in rural and remote areas, which limits access to advanced diagnostic technologies. While urban centers have seen rapid advancements, the lack of diagnostic facilities in rural regions poses a significant barrier to widespread adoption. Additionally, high costs associated with advanced diagnostic tests, such as molecular diagnostics and point-of-care testing, can limit their affordability and accessibility, especially for underserved populations. Regulatory hurdles and delays in approvals for new diagnostic technologies also slow down the market's growth, as the introduction of innovative solutions often faces bureaucratic obstacles. Furthermore, while the demand for diagnostics is rising, there is often a lack of trained professionals to effectively operate advanced diagnostic equipment, which hampers the effective utilization of available technologies. These challenges highlight the need for targeted investment in healthcare infrastructure, affordability strategies, and capacity-building initiatives to unlock the full potential of the diagnostic market in India.

Market Lifecycle Stage of India Emerging Infectious Disease Diagnostics:

The India Emerging Infectious Disease Diagnostics market is currently in a phase of rapid growth and innovation. This phase is characterized by the increasing adoption of advanced diagnostic technologies, driven by the rising incidence of infectious diseases, particularly COVID-19, malaria, tuberculosis, and dengue. The market is also benefiting from significant government investments in healthcare infrastructure and diagnostic capabilities, as well as from private sector participation in expanding access to diagnostic tools. Technological advancements in molecular diagnostics, point-of-care testing, and artificial intelligence are enabling faster, more accurate detection of infectious diseases, further propelling market growth. As the demand for more efficient and accessible diagnostic solutions grows, the market is in the process of scaling up, with an increasing number of diagnostic centers and partnerships with international companies. However, challenges related to affordability, infrastructure gaps, and regulatory processes still need to be addressed as the market continues to mature.

Impact on India Emerging Infectious Disease Diagnostics

India Emerging Infectious Disease Diagnostics market is experiencing rapid growth, driven by increasing technological advancements, heightened public health awareness, and government initiatives aimed at strengthening healthcare infrastructure. This sector plays a critical role in addressing the growing burden of infectious diseases, enabling timely detection, and improving disease management. The market includes a broad range of diagnostic solutions, such as molecular diagnostics, point-of-care testing, and rapid diagnostic tests (RDTs), all of which are transforming the approach to combating infectious diseases in India.

Key technological advancements in India emerging infectious disease diagnostics include:

• Molecular Diagnostics: The adoption of molecular diagnostic technologies, such as Polymerase Chain Reaction (PCR) and Real-Time PCR (RT-PCR), has revolutionized the ability to detect pathogens with higher accuracy and speed. These technologies, which allow for the precise identification of viral and bacterial infections at a genetic level, have become indispensable in the rapid diagnosis of diseases such as COVID-19, tuberculosis, and malaria.
• Point-of-Care Testing (POCT): Point-of-care testing devices have been gaining traction in India, enabling rapid diagnosis at the site of patient care. This is especially important in rural and underserved areas where access to centralized laboratories may be limited. POCT technologies, such as rapid antigen and antibody tests, have proven to be effective in detecting diseases such as dengue, malaria, and COVID-19.
• Artificial Intelligence (AI): AI and machine learning are increasingly being incorporated into diagnostic platforms, improving the efficiency of disease detection and interpretation of results. AI-driven diagnostic tools are helping streamline data analysis, enabling faster decision-making and better patient outcomes.

Impact of India Emerging Infectious Disease Diagnostics:

India faces a dual burden of communicable diseases and non-communicable diseases, with infectious diseases continuing to pose significant public health challenges. The rise of emerging infectious diseases, such as COVID-19, as well as vector-borne diseases (dengue, chikungunya), and zoonotic diseases, has created an urgent demand for more sophisticated and widespread diagnostic tools.

The COVID-19 pandemic significantly accelerated the adoption of diagnostic testing in India, highlighting the importance of having a robust diagnostic infrastructure for emerging diseases. This shift has brought global attention to the need for improved diagnostic capabilities, and it has encouraged investments in both public and private sectors to enhance diagnostic services across the country.

Government Initiatives and Support:

The Indian government has been proactive in addressing the diagnostic needs for infectious diseases through initiatives such as the National Health Mission (NHM), National Tuberculosis Elimination Program (NTEP), and Integrated Disease Surveillance Program (IDSP). These initiatives aim to improve disease surveillance, early detection, and treatment access, which directly influences the demand for diagnostic services.

In response to COVID-19, the government ramped up efforts to increase diagnostic testing capacity, including expanding testing sites, subsidizing diagnostic kits, and streamlining approval processes for new diagnostic technologies. These actions have significantly improved India's capacity to respond to infectious disease outbreaks and have laid the foundation for future diagnostic infrastructure development.

Market Segmentation for Impact on India Emerging Infectious Disease Diagnostics Market:

Segmentation 1: by Application

• Laboratory Testing
• Point of Care

Laboratory Testing to Dominate the India Emerging Infectious Disease Diagnostics Market (by Application)

Based on application, the laboratory testing segment dominated India emerging infectious disease diagnostics market in FY2024. Laboratory testing plays a crucial role in the diagnosis and management of infectious diseases. It involves the analysis of patient samples, such as blood, urine, sputum, or tissue, to detect the presence of infectious agents. Microbiological culture is a common technique that involves incubating patient samples on specific growth media to isolate and identify bacteria, fungi, or parasites, which can then be visualized through microscopy.

Segmentation 2: by Technology

• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Next-Generation Sequencing (NGS)
• Immunodiagnostics
• Other Technologies

Based on technology, India emerging infectious disease diagnostics market was dominated by the PCR segment in FY2024. Nowadays, PCR is usually used in several laboratories around the world, as it amplifies DNA further, allowing the analysis of even small amounts of nucleic acid. With growing technological advancements in molecular biology techniques, PCR has been utilized in several fields, including disease diagnosis, DNA profiling, precision medicine, and gene expression.

Next-generation sequencing (NGS) has revolutionized infectious disease diagnosis by enabling comprehensive and high-throughput analysis of pathogen genomes. Whole genome sequencing (WGS) allows the sequencing of entire pathogen genomes, providing detailed information about genetic variations, antimicrobial resistance genes, and virulence factors. It can identify and characterize pathogens, track outbreaks, and analyze their evolutionary patterns.

Other emerging technologies anticipated to register significant growth include technologies such as digital PCR, INAAT, and clustered regularly interspaced short palindromic repeats (CRISPR).

Segmentation 3: by Type of Infection

• Bacterial
• Viral
• Fungal
• Other Infections (Parasitic etc)

Bacterial and Viral Segments to Dominate the India Emerging Infectious Disease Diagnostics Market (by Type of Infection)

Based on the type of infection, bacterial infectious disease diagnosis involves various methods and techniques to identify the presence of bacterial pathogens in clinical samples. Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.

Viruses have the ability to mutate and, therefore, can lead to the re-emergence of diseases even after one form of the virus has been eradicated or managed. Molecular diagnostic companies are therefore focused on developing tests that can detect a wide range of viruses. Some of the common infections caused by viruses include influenza, genital herpes, COVID-19, hepatitis, mumps, rubella, gastroenteritis, Zika disease, and ebola disease, among others.

Segmentation 4: by Disease Type

• Respiratory Infections
• Gastrointestinal Infections
• Sexually Transmitted Infections (STIs)
• Neurological Infections
• Post-Transplant Infections
• Other Infections

Respiratory Infections to Dominate the India Emerging Infectious Disease Diagnostics Market (by Disease Type)

A vast majority of molecular diagnostic companies offer tests for various kinds of bacteria and viruses responsible for causing respiratory infections. Moreover, the COVID-19 pandemic led to the development of a wide range of tests employing conventional technologies such as reverse transcriptase PCR (RT-PCR) and even leveraging emerging technologies such as RT-LAMP and CRISPR. Several companies now offer multiplex assays that test for influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 virus.

Segmentation 5: by End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Other End Users

Hospitals and Clinics and Diagnostic Laboratories to Dominate the India Emerging Infectious Disease Diagnostics Market (by End User)

Based on end users, the hospitals and clinics, and diagnostic laboratories segments accounted for the largest share of the India emerging infectious disease diagnostics market in FY2024. Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing. In addition to point-of-care testing (POCT), which provides immediate results for rapid diagnosis and management, hospitals and clinics may also rely on laboratory testing for comprehensive analysis. Some healthcare facilities have on-site laboratories equipped with state-of-the-art diagnostic technologies, while others collaborate with external diagnostic laboratories for specialized testing. These laboratory facilities employ various methods, including molecular techniques such as PCR and sequencing, serological assays, and culture-based methods to identify and characterize infectious agents accurately.

Recent Developments in the India Emerging Infectious Disease Diagnostics Market

• In February 2023, Thermo Fisher Scientific Inc. and Mylab announced a pact on test kits for infectious diseases.
• In February 2023, Biotech startup CrisprBits raised $250,000 in a pre-seed funding round to support the development and commercialization of its CRISPR-based tests.
• In February 2023, the Food and Drug Administration (FDA) authorized the Xpert Mpox test by Cepheid (parent: DANAHER CORPORATION) for emergency use.
• In August 2022, Bio-Rad Laboratories, Inc. acquired Curiosity Diagnostics to gain access to PCR ONE, a technology being developed by Curiosity Diagnostics, which can quickly detect a broad range of pathogens.
• In June 2021, Hologic, Inc. completed the acquisition of Mobidiag to expand its capabilities in molecular diagnostics.
• In January 2023, CrisprBits developed India's first CRISPR-based SARS-CoV-2 test with Omicron detection.
• In March 2023, an India-based startup, Mylab Discovery Solutions Pvt. Ltd., entered into a joint venture with AstraGene LLC, the U.A.E.'s first molecular diagnostics manufacturing company to develop molecular diagnostics in the U.A.E. and Kuwait.
• In November 2022, Bio-Rad Laboratories, Inc. and NuProbe entered into an exclusive licensing agreement for digital PCR applications.

How can India emerging infectious disease diagnostics market report add value to an organization?

Workflow/Innovation Strategy: India emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: In the India emerging infectious disease diagnostics market product launches, upgradations, and approvals accounted for the maximum number of key developments.

Competitive Strategy: The India emerging infectious disease diagnostics market is fragmented with several established as well as emerging players. Key players in the India emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

Methodology

Key Considerations and Assumptions in India Emerging Infectious Disease Diagnostics Market Engineering and Validation

• The base year considered for the calculation of India emerging infectious disease diagnostics market size is 2024. The historical year analysis has been done from FY2021 to FY2023, and the market size has been estimated for FY2024 and projected for the period 2025-2035.
• The regional distribution of the India emerging infectious disease diagnostics market revenue has been estimated to be the same as the company's net revenue distribution. All the numbers have been adjusted off to two digits after decimal for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. The CAGR has been calculated for the forecast period 2025-2035.
• The market has been mapped based on different types of products available in the India emerging infectious disease diagnostics market for various applications. All key companies having a significant number of offerings for the India emerging infectious disease diagnostics market have been considered and profiled in the report.
• The primary respondent's verification has been considered to finalize the estimated market for the India emerging infectious disease diagnostics market.
• The latest annual reports of each market player have been taken into consideration for India emerging infectious disease diagnostics market revenue calculation.
• Market strategies and developments of key players have been considered for the calculation of the sub-segment split.
• The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website.

Primary Research

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding of the numbers of the various markets for market type
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), Global Burden Disease (GBD), World Health Organization (WHO), and Indian Council of Medical Research (ICMR)
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolio
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentations, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players in the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis for India Emerging Infectious Disease Diagnostics:

Infectious disease diagnostics encompass a range of methods and techniques used to identify and detect infectious agents in individuals suspected of having an infection. These diagnostics play a vital role in timely diagnosis and accuracy, enabling appropriate treatment decisions and public health interventions.

There are two major approaches in the field; one is microbiological culture, which is a fundamental approach in which patient specimens are cultured on specialized growth media to isolate and identify specific pathogens. This technique allows for the determination of the causative organism and the assessment of its antimicrobial susceptibility. Molecular diagnostics, another important approach, utilizes techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) to detect the genetic material of the infectious agent. This enables highly sensitive and specific identification of pathogens, even at low concentrations.

Some of the prominent companies in India emerging infectious disease diagnostics market are:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Becton, Dickinson and Company
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Siemens Healthcare AG
• Thermo Fisher Scientific Inc.
• DANAHER CORPORATION
• Hologic, Inc.
• Trivitron Healthcare
• Genes2Me
• CrisprBits
• D-NOME Pvt Ltd
• Co-Diagnostics, Inc.
• DiaSorin S.p.A.
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope of Study

Research Methodology

1. India Emerging Infectious Disease Diagnostics Market Overview

• 1.1 Market Outlook
  • 1.1.1 Market Overview
    • 1.1.1.1 Epidemiology of Infectious Diseases In India
      • 1.1.1.1.1 Respiratory Infection
        • 1.1.1.1.1.1 Influenza A and B
        • 1.1.1.1.1.1.1 Incidence
        • 1.1.1.1.1.1.2 Diagnosis rate
        • 1.1.1.1.1.1.3 Target Patient Pool
        • 1.1.1.1.1.2 RSV
        • 1.1.1.1.1.2.1 Incidence
        • 1.1.1.1.1.2.2 Diagnosis rate
        • 1.1.1.1.1.2.3 Target Patient Pool
        • 1.1.1.1.1.3 Mycoplasma Infections
        • 1.1.1.1.1.3.1 Incidence
        • 1.1.1.1.1.3.2 Diagnosis rate
        • 1.1.1.1.1.3.3 Target Patient Pool
        • 1.1.1.1.1.4 Pertussis
        • 1.1.1.1.1.4.1 Incidence
        • 1.1.1.1.1.4.2 Diagnosis rate
        • 1.1.1.1.1.4.3 Target Patient Pool
        • 1.1.1.1.1.5 Sexually Transmitted Infections (STIs)
        • 1.1.1.1.1.5.1 Incidence
        • 1.1.1.1.1.5.2 Diagnosis rate
        • 1.1.1.1.1.5.3 Target Patient Pool
        • 1.1.1.1.1.6 HIV/AIDS
        • 1.1.1.1.1.6.1 Incidence
        • 1.1.1.1.1.6.2 Diagnosis rate
        • 1.1.1.1.1.6.3 Target Patient Pool
        • 1.1.1.1.1.7 HPV Infection
        • 1.1.1.1.1.7.1 Incidence
        • 1.1.1.1.1.7.2 Diagnosis rate
        • 1.1.1.1.1.7.3 Target Patient Pool
        • 1.1.1.1.1.8 Herpes
        • 1.1.1.1.1.8.1 Incidence
        • 1.1.1.1.1.8.2 Diagnosis rate
        • 1.1.1.1.1.8.3 Target Patient Pool
        • 1.1.1.1.1.9 Gonorrhoea
        • 1.1.1.1.1.9.1 Incidence
        • 1.1.1.1.1.9.2 Diagnosis rate
        • 1.1.1.1.1.9.3 Target Patient Pool
        • 1.1.1.1.1.10 Syphilis
        • 1.1.1.1.1.10.1 Incidence
        • 1.1.1.1.1.10.2 Diagnosis rate
        • 1.1.1.1.1.10.3 Target Patient Pool
      • 1.1.1.1.2 Gastrointestinal Infections
        • 1.1.1.1.2.1 Colitis
        • 1.1.1.1.2.1.1 Incidence
        • 1.1.1.1.2.1.2 Diagnosis rate
        • 1.1.1.1.2.1.3 Target Patient Pool
        • 1.1.1.1.2.2 Peptic Ulcer
        • 1.1.1.1.2.2.1 Incidence
        • 1.1.1.1.2.2.2 Diagnosis rate
        • 1.1.1.1.2.2.3 Target Patient Pool
        • 1.1.1.1.2.3 Diarrhoea
        • 1.1.1.1.2.3.1 Incidence
        • 1.1.1.1.2.3.2 Diagnosis rate
        • 1.1.1.1.2.3.3 Target Patient Pool
      • 1.1.1.1.3 Neurological Infections
        • 1.1.1.1.3.1 Meningitis
        • 1.1.1.1.3.1.1 Incidence
        • 1.1.1.1.3.1.2 Diagnosis rate
        • 1.1.1.1.3.1.3 Target Patient Pool
        • 1.1.1.1.3.2 Encephalitis
        • 1.1.1.1.3.2.1 Incidence
        • 1.1.1.1.3.2.2 Diagnosis rate
        • 1.1.1.1.3.2.3 Target Patient Pool
      • 1.1.1.1.4 Post-Transplant Infections
        • 1.1.1.1.4.1 CMV Infection
        • 1.1.1.1.4.1.1 Incidence
        • 1.1.1.1.4.1.2 Diagnosis rate
        • 1.1.1.1.4.1.3 Target Patient Pool
        • 1.1.1.1.4.2 Sepsis
        • 1.1.1.1.4.2.1 Incidence
        • 1.1.1.1.4.2.2 Diagnosis rate
        • 1.1.1.1.4.2.3 Target Patient Pool
        • 1.1.1.1.4.3 Antimicrobial Resistance
        • 1.1.1.1.4.3.1 Microbe Resistance
        • 1.1.1.1.4.3.2 Key Causative Agent
        • 1.1.1.1.4.3.3 Preventive Measures to Limit AMR
        • 1.1.1.1.4.3.4 Challenges
  • 1.1.2 Most Preferred Platform for Infectious Disease Diagnosis
    • 1.1.2.1 Rapid Antigen Test (RAT)
    • 1.1.2.2 Polymerase Chain Reaction (PCR)
    • 1.1.2.3 Next Generation Sequencing (NGS)
  • 1.1.3 Timeline of Emerging Technologies for Infectious Disease Diagnostics
  • 1.1.4 Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
  • 1.1.5 Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
• 1.2 Market Dynamics
  • 1.2.1 Market Opportunities and Trends
  • 1.2.2 Market Drivers
    • 1.2.2.1 Impact Analysis
  • 1.2.3 Market Restraints
    • 1.2.3.1 Impact Analysis

2. India Emerging Infectious Disease Diagnostics Market Analysis (by Application), $Million, 2023-2035

• 2.1 Overview
• 2.2 Laboratory Testing
• 2.3 Point-of-Care Testing

3. India Emerging Infectious Disease Diagnostics Market Analysis (by Technology), $Million, 2023-2035

• 3.1 Overview
• 3.2 PCR
  • 3.2.1 Real Time PCR
  • 3.2.2 Digital PCR
• 3.3 Immunodiagnostics
• 3.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
• 3.5 Next Generation Sequencing (NGS)
• 3.6 Other Technologies

4. India Emerging Infectious Disease Diagnostics Market Analysis (by Type of Infection), $Million, 2023-2035

• 4.1 Overview
• 4.2 Bacterial
• 4.3 Viral
• 4.4 Fungal
• 4.5 Other Infections (Parasite)

5. India Emerging Infectious Disease Diagnostics Market Analysis (By Disease Type), $Million, 2023-2035

• 5.1 Overview
• 5.2 Respiratory Infection
• 5.3 Gastrointestinal Infection
• 5.4 Sexually Transmitted Infections (STIs)
• 5.5 Neurological Infection
• 5.6 Post-Transplant Infection
• 5.7 Other Infection

6. India Emerging Infectious Disease Diagnostics Market Analysis (By End User), $Million, 2023-2035

• 6.1 Overview
• 6.2 Hospitals and Clinics
• 6.3 Diagnostic Laboratories
• 6.4 Other End User

7. India Emerging Infectious Disease Diagnostics Market - Competitive Benchmarking and Company Profiles

• 7.1 Competitive Benchmarking
• 7.2 Competitive Landscape
  • 7.2.1 Key Strategies and Developments by Company
    • 7.2.1.1 Funding Activities
    • 7.2.1.2 Mergers and Acquisitions
    • 7.2.1.3 Regulatory Approvals
    • 7.2.1.4 Partnerships, Collaborations and Business Expansions
  • 7.2.2 Key Developments Analysis
  • 7.2.3 Company Share Analysis
• 7.3 Company Profiles
  • 7.3.1 Abbott Laboratories
    • 7.3.1.1 Company Overview
    • 7.3.1.2 Product Portfolio
    • 7.3.1.3 Target Customers/End Users
    • 7.3.1.4 Analyst View
  • 7.3.2 Becton, Dickson and Company
    • 7.3.2.1 Company Overview
    • 7.3.2.2 Product Portfolio
    • 7.3.2.3 Target Customers/End Users
    • 7.3.2.4 Analyst View
  • 7.3.3 bioMerieux S.A.
    • 7.3.3.1 Company Overview
    • 7.3.3.2 Product Portfolio
    • 7.3.3.3 Target Customers/End Users
    • 7.3.3.4 Analyst View
  • 7.3.4 Bio-Rad Laboratories, Inc
    • 7.3.4.1 Company Overview
    • 7.3.4.2 Product Portfolio
    • 7.3.4.3 Target Customers/End Users
    • 7.3.4.4 Analyst View
  • 7.3.5 Co-Diagnostics, Inc.
    • 7.3.5.1 Company Overview
    • 7.3.5.2 Product Portfolio
    • 7.3.5.3 Target Customers/End Users
    • 7.3.5.4 Analyst View
  • 7.3.6 Danaher Corporation
    • 7.3.6.1 Company Overview
    • 7.3.6.2 Product Portfolio
    • 7.3.6.3 Target Customers/End Users
    • 7.3.6.4 Analyst View
  • 7.3.7 DiaSorin S.p.A
    • 7.3.7.1 Company Overview
    • 7.3.7.2 Product Portfolio
    • 7.3.7.3 Target Customers/End Users
    • 7.3.7.4 Analyst View
  • 7.3.8 F. Hoffmann-La Roche Ltd
    • 7.3.8.1 Company Overview
    • 7.3.8.2 Product Portfolio
    • 7.3.8.3 Target Customers/End Users
    • 7.3.8.4 Analyst View
  • 7.3.9 Hologic, Inc
    • 7.3.9.1 Company Overview
    • 7.3.9.2 Product Portfolio
    • 7.3.9.3 Target Customers/End Users
    • 7.3.9.4 Analyst View
  • 7.3.10 QIAGEN N.V.
    • 7.3.10.1 Company Overview
    • 7.3.10.2 Product Portfolio
    • 7.3.10.3 Target Customers/End Users
    • 7.3.10.4 Analyst View
  • 7.3.11 Thermo Fisher Scientific, Inc.
    • 7.3.11.1 Company Overview
    • 7.3.11.2 Product Portfolio
    • 7.3.11.3 Target Customers/End Users
    • 7.3.11.4 Analyst View
  • 7.3.12 Siemens Healthineers AG
    • 7.3.12.1 Company Overview
    • 7.3.12.2 Product Portfolio
    • 7.3.12.3 Target Customers/End Users
    • 7.3.12.4 Analyst View
• 7.4 Emerging Companies Snapshot
  • 7.4.1 Trivitron Healthcare
  • 7.4.2 Genes2Me
  • 7.4.3 CrisprBits
  • 7.4.4 D-NOME Pvt Ltd.

8. Research Methodology